Stock CABA CABALETTA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
11.01 USD -9.61% Intraday chart for Cabaletta Bio, Inc. -17.47% -51.50%
Mar. 22 HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating MT
Mar. 21 Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Number of employees: 102

Managers

Managers TitleAgeSince
Steven Nichtberger CEO
 Chief Executive Officer 62 17-03-31
Anup Marda DFI
 Director of Finance/CFO 46 18-12-31
Heather Harte-Hall CMP
 Compliance Officer - 19-02-28
Samik Basu CTO
 Chief Tech/Sci/R&D Officer - 19-11-30
David Chang CTO
 Chief Tech/Sci/R&D Officer 61 19-05-31
Gwendolyn Binder-Scholl CTO
 Chief Tech/Sci/R&D Officer 49 19-01-31
Martha O'Connor HRO
 Human Resources Officer - 19-02-28
Arun Das PRN
 Corporate Officer/Principal 34 19-06-30
Michael Gerard LAW
 General Counsel 44 21-09-06

Members of the board

Members of the board TitleAgeSince
Richard Henriques BRD
 Director/Board Member 68 19-02-18
Steven Nichtberger CEO
 Chief Executive Officer 62 17-03-31
Mark Simon BRD
 Director/Board Member 62 18-09-30
Shawn Tomasello BRD
 Director/Board Member 65 23-07-20
Scott Brun BRD
 Director/Board Member 56 21-06-23
Catherine Bollard BRD
 Director/Board Member 56 19-04-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 46,804,820 43,288,135 ( 92.49 %) 0 92.49 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
7.897 %
3,809,766 7.897 % 65 M $
Fred Alger Management LLC (13f Subfiler)
6.897 %
3,327,132 6.897 % 57 M $
Adage Capital Partners GP LLC
6.771 %
3,266,645 6.771 % 56 M $
STATE STREET CORPORATION
5.378 %
2,594,470 5.378 % 44 M $
Venrock Associates
5.315 %
2,563,952 5.315 % 44 M $
Vanguard Fiduciary Trust Co.
4.419 %
2,131,931 4.419 % 36 M $
Lynx1 Capital Management LP
4.375 %
2,110,401 4.375 % 36 M $
Deerfield Management Co. LP (Private Equity)
4.162 %
2,007,729 4.162 % 34 M $
Perceptive Advisors LLC
4.152 %
2,003,058 4.152 % 34 M $
Bain Capital Life Sciences LP
4.146 %
2,000,000 4.146 % 34 M $

Company contact information

Cabaletta Bio, Inc.

2929 Arch Street Suite 600

19104, Philadelphia

+

http://www.cabalettabio.com
address Cabaletta Bio, Inc.(CABA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.01 USD
Average target price
34.5 USD
Spread / Average Target
+213.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CABALETTA BIO, INC. Stock Cabaletta Bio, Inc.
-51.50% 531M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CABA Stock
  4. Company Cabaletta Bio, Inc.